dalteparin has been researched along with Postpartum Hemorrhage in 11 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Postpartum Hemorrhage: Excess blood loss from uterine bleeding associated with OBSTETRIC LABOR or CHILDBIRTH. It is defined as blood loss greater than 500 ml or of the amount that adversely affects the maternal physiology, such as BLOOD PRESSURE and HEMATOCRIT. Postpartum hemorrhage is divided into two categories, immediate (within first 24 hours after birth) or delayed (after 24 hours postpartum).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 9.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 5.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| "The evaluation criteria for dosage of low-molecular-weight heparin (LMWH) for pregnant women at high risk of venous thromboembolism (VTE) remain unclear." | 1.72 | Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women. ( Guo, L; Luo, Y; Mu, L; Xiao, S; Ye, Z; Zhang, J, 2022) |
| "High rates of postpartum hemorrhage are reported in our cohort." | 1.51 | Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism. ( Cox, S; Eslick, R; McLintock, C, 2019) |
| " For those records documenting tinzaparin use and pregnancy outcome, information was extracted into a standardised case report form; these were reviewed for adverse events, which were submitted for adjudication by independent experts in obstetric medicine and haematology." | 1.37 | Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. ( Borg, JY; Greer, IA; Nelson-Piercy, C; Powrie, R; Rodger, M; Stinson, J; Talbot, DJ, 2011) |
| "Given that deep vein thrombosis coincided with obstetric delivery, it was crucial to decide on anesthetic and therapeutic approaches that would assure maternal and fetal safety and prevent such complications as massive pulmonary thromboembolism." | 1.36 | [Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. ( Amorós, B; Bermejo, L; Dueñas, N; Fernández, E; Perea, M; Villafranca, A, 2010) |
| "Severe postpartum hemorrhage is an infrequent complication when enoxaparin is administered to hemostatically intact women between 5 and 24 h following a vaginal delivery or 12-36 h following cesarean section." | 1.35 | Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. ( Bauer, KA; Freedman, RA; Neuberg, DS; Zwicker, JI, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bailly, J | 1 |
| Jacobson, BF | 1 |
| Louw, S | 1 |
| Cox, S | 1 |
| Eslick, R | 1 |
| McLintock, C | 1 |
| Schaal, JV | 1 |
| Benhamou, D | 1 |
| Boyer, K | 1 |
| Mercier, FJ | 1 |
| Fernández, E | 1 |
| Dueñas, N | 1 |
| Villafranca, A | 1 |
| Perea, M | 1 |
| Amorós, B | 1 |
| Bermejo, L | 1 |
| Freedman, RA | 1 |
| Bauer, KA | 1 |
| Neuberg, DS | 1 |
| Zwicker, JI | 1 |
| Xiao, S | 1 |
| Luo, Y | 1 |
| Guo, L | 1 |
| Zhang, J | 1 |
| Mu, L | 1 |
| Ye, Z | 1 |
| Hellgren, M | 1 |
| Mistafa, O | 1 |
| Isma, N | 1 |
| Svensson, PJ | 1 |
| Lindblad, B | 1 |
| Lindqvist, PG | 1 |
| Gredilla, E | 1 |
| Pérez-Ferrer, A | 1 |
| Canser, E | 1 |
| Alonso, E | 1 |
| Martínez Serrano, B | 1 |
| Gilsanz, F | 1 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| Murphy, K | 1 |
| McAuliffe, F | 1 |
| Byrne, B | 1 |
| Nelson-Piercy, C | 1 |
| Powrie, R | 1 |
| Borg, JY | 1 |
| Rodger, M | 1 |
| Talbot, DJ | 1 |
| Stinson, J | 1 |
| Greer, IA | 1 |
1 review available for dalteparin and Postpartum Hemorrhage
| Article | Year |
|---|---|
Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Postpartum Hemorrhage; Pregnancy; Pregnancy Compl | 2019 |
10 other studies available for dalteparin and Postpartum Hemorrhage
| Article | Year |
|---|---|
Safety and efficacy of adjusted-dose enoxaparin in pregnant patients with increased risk for venous thromboembolic disease.
Topics: Adult; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Postpartum Hemo | 2019 |
Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism.
Topics: Adult; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; | 2019 |
[Parkes-Weber syndrome and pregnancy: anaesthetic implications].
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants; Arteriovenous Malformations; Emb | 2013 |
[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery].
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anticoagulants; Cesarean Section; Emergencies; | 2010 |
Timing of postpartum enoxaparin administration and severe postpartum hemorrhage.
Topics: Adult; Anticoagulants; Case-Control Studies; Cesarean Section; Drug Administration Schedule; Enoxapa | 2008 |
Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women.
Topics: Anticoagulants; Dalteparin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Postpartum Hemor | 2022 |
The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour.
Topics: Adult; Anticoagulants; Case-Control Studies; Chi-Square Distribution; Dalteparin; Female; Gestationa | 2010 |
[Treating severe acute anemia due to vaginal bleeding in the Jehovah's Witness: a report of 2 cases].
Topics: Adult; Anemia; Anti-Anxiety Agents; Anticoagulants; Cervix Uteri; Combined Modality Therapy; Contrac | 2009 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile.
Topics: Adolescent; Adult; Canada; Cohort Studies; Europe; Female; Fibrinolytic Agents; Heparin, Low-Molecul | 2011 |